Sugi Predict

Sugi Predict / Targets / CNR1

CNR1

Cannabinoid receptor 1 · P21554 · CNR1 on Sugi Atlas →

584,515 patent compounds predicted against CNR1, 314,458 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Lenabasum Lenabasum (SCHEMBL26441) 1.00 13/20
Nabilone Nabilone (SCHEMBL33339) 1.00 12/20
Dronabinol Dronabinol (SCHEMBL4609) 1.00 10/20
SCHEMBL39060 SCHEMBL39060 0.44 10/20
Rimonabant Rimonabant (SCHEMBL38637) 1.00 9/20
SCHEMBL40013 SCHEMBL40013 0.48 8/20
Anandamide Anandamide (SCHEMBL43143) 1.00 7/20
Anandamide Anandamide (SCHEMBL43144) 1.00 7/20
SCHEMBL18671 SCHEMBL18671 0.53 7/20
Fenofibrate Fenofibrate (SCHEMBL4670) 1.00 6/20
SCHEMBL23820 SCHEMBL23820 0.66 6/20
SCHEMBL23821 SCHEMBL23821 0.66 6/20
Diflubenzuron Diflubenzuron (SCHEMBL42416) 0.52 6/20
SCHEMBL29669 SCHEMBL29669 0.41 6/20
Cerulenin Cerulenin (SCHEMBL41207) 0.37 6/20
SCHEMBL39361 SCHEMBL39361 0.32 6/20
Orlistat Orlistat (SCHEMBL16408) 1.00 5/20
SCHEMBL43416 SCHEMBL43416 0.77 5/20
SCHEMBL38999 SCHEMBL38999 0.71 5/20
SCHEMBL39282 SCHEMBL39282 0.71 5/20

Clinical trials — most relevant to CNR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment Strategies in CHS PHASE4COMPLETED
Investigating the Effects of Nabilone on Endocannabinoid Metabolism PHASE4COMPLETED
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors PHASE2/PHASE3COMPLETED
Sativex for Treatment of Chemotherapy Induced Neuropathic Pain PHASE3COMPLETED
Topical Cannabidiol for Treating Carpal Tunnel Syndrome PHASE2NOT_YET_RECRUITING
Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) PHASE1/PHASE2RECRUITING
Effect of Hemp-CBD on Patients With CIPN PHASE2UNKNOWN
Nabilone for Non-motor Symptoms in Parkinson's Disease PHASE2COMPLETED
Treatment for Cannabis Withdrawal and Dependence PHASE2COMPLETED
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes PHASE1COMPLETED
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults PHASE1COMPLETED
A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population PHASE1COMPLETED
Cannabinoids, Learning, and Memory PHASE1ACTIVE_NOT_RECRUITING
Imaging of Cannabinoid Receptors Using New Radioactive Tracer PHASE1COMPLETED
The Role of Endocannabinoids in Insulin Production and Action PHASE1COMPLETED
Antagonist-Elicited Cannabis Withdrawal PHASE1COMPLETED
PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2 PHASE1COMPLETED
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity PHASE1ACTIVE_NOT_RECRUITING
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence nanCOMPLETED
Effect of OMM on Anandamide Levels in Saliva nanCOMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Acute and Chronic Toxicity of Some Synthetic Cannabinoids in Assiut Psychiatric Hospitals nanUNKNOWN
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery nanCOMPLETED
Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region nanCOMPLETED
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity nanCOMPLETED
Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana nanCOMPLETED
Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET nanCOMPLETED
Cannabinoids for Osteoarthritis Pain Effectiveness Trial nanRECRUITING
Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms nanCOMPLETED
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a CNR1 binder may also engage these)

ProteinNameSimilarity
Q71SP5 — 1.000 Q71SP5 →
O02777 — 1.000 O02777 →
P47746 — 1.000 P47746 →
Q5IS73 — 1.000 Q5IS73 →
Q9PUI7 — 1.000 Q9PUI7 →
P56971 — 1.000 P56971 →
Q333S9 — 1.000 Q333S9 →
Q801M1 — 0.999 Q801M1 →
Q98895 — 0.999 Q98895 →
P20272 — 0.997 P20272 →
Q98894 — 0.997 Q98894 →
P48303 — 0.978 P48303 →
Q99680 — 0.978 Q99680 →
Q91178 — 0.977 Q91178 →
D4A3U0 — 0.976 D4A3U0 →
Q8BZL4 — 0.974 Q8BZL4 →
A0A2R9YJI3 — 0.972 A0A2R9YJI3 →
Q9DDK4 — 0.972 Q9DDK4 →
Q9I8K8 — 0.971 Q9I8K8 →
O08530 — 0.969 O08530 →
S1PR1 Sphingosine 1-phosphate receptor 1 0.969 landscape →
B4XF06 — 0.968 B4XF06 →
Q9PUQ8 — 0.968 Q9PUQ8 →
Q5U431 — 0.968 Q5U431 →
P17200 — 0.968 P17200 →
Q5E9P3 — 0.967 Q5E9P3 →
HTR2C 5-hydroxytryptamine receptor 2C 0.967 landscape →
Q75Z89 — 0.966 Q75Z89 →
GPR39 G-protein coupled receptor 39 0.964 landscape →
O46635 — 0.964 O46635 →